[HTML][HTML] Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets

L Beumers, EI Vlachavas, S Borgoni… - NPJ Breast …, 2023 - nature.com
Intratumoral heterogeneity impacts the success or failure of anti-cancer therapies. Here, we
investigated the evolution and mechanistic heterogeneity in clonal populations of cell …

Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets.

L Beumers, EI Vlachavas, S Borgoni… - NPJ Breast …, 2023 - search.ebscohost.com
Intratumoral heterogeneity impacts the success or failure of anti-cancer therapies. Here, we
investigated the evolution and mechanistic heterogeneity in clonal populations of cell …

Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets

L Beumers, EI Vlachavas, S Borgoni… - NPJ Breast …, 2023 - search.proquest.com
Intratumoral heterogeneity impacts the success or failure of anti-cancer therapies. Here, we
investigated the evolution and mechanistic heterogeneity in clonal populations of cell …

Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets.

L Beumers, EI Vlachavas, S Borgoni… - NPJ Breast …, 2023 - europepmc.org
Intratumoral heterogeneity impacts the success or failure of anti-cancer therapies. Here, we
investigated the evolution and mechanistic heterogeneity in clonal populations of cell …

Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets

L Beumers, EI Vlachavas, S Borgoni… - npj Breast …, 2023 - weizmann.elsevierpure.com
Intratumoral heterogeneity impacts the success or failure of anti-cancer therapies. Here, we
investigated the evolution and mechanistic heterogeneity in clonal populations of cell …

Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets

L Beumers, EI Vlachavas, S Borgoni… - NPJ breast …, 2023 - pubmed.ncbi.nlm.nih.gov
Intratumoral heterogeneity impacts the success or failure of anti-cancer therapies. Here, we
investigated the evolution and mechanistic heterogeneity in clonal populations of cell …

[PDF][PDF] Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets

L Beumers, EI Vlachavas, S Borgoni, L Schwarzmüller… - bookcafe.yuntsg.com
Intratumoral heterogeneity impacts the success or failure of anti-cancer therapies. Here, we
investigated the evolution and mechanistic heterogeneity in clonal populations of cell …

[HTML][HTML] Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets

L Beumers, EI Vlachavas, S Borgoni… - NPJ Breast …, 2023 - ncbi.nlm.nih.gov
Intratumoral heterogeneity impacts the success or failure of anti-cancer therapies. Here, we
investigated the evolution and mechanistic heterogeneity in clonal populations of cell …

Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets.

L Beumers, EI Vlachavas, S Borgoni… - NPJ Breast …, 2023 - europepmc.org
Intratumoral heterogeneity impacts the success or failure of anti-cancer therapies. Here, we
investigated the evolution and mechanistic heterogeneity in clonal populations of cell …